Molecular Diagnostics News and Research

RSS

AMP announces Council's unanimous approval of strategic plan for personalized medicine

The Association for Molecular Pathology (AMP) today announced the AMP Council's unanimous approval of a strategic plan intended to guide the organization over the next four years.

19 Nov 2011

MDxHealth total revenues decrease 7% for third quarter 2011

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the third quarter and for the nine months ended September 30, 2011.

17 Nov 2011

CF Foundation, Genzyme announce new drug research agreement

Genzyme, a Sanofi company, and Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, today announced a research agreement to support the discovery of new drugs to treat people with the most common mutation found in patients with CF, Delta F508.

17 Nov 2011

Positive data from MDxHealth's prostate cancer test study

MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced data showing that a prototype of its Prostate ConfirmMDx test can help urologists distinguish patients who have a true negative biopsy from those who may have occult cancer undetected by prostate biopsy and histopathological review.

15 Nov 2011

Highmark now covers AlloMap for monitoring heart transplant rejection

XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive diagnostic tests to monitor immune-mediated conditions, today announced that Highmark Inc., an independent licensee of the Blue Cross Blue Shield Association, is now covering AlloMap for its beneficiaries.

9 Nov 2011

NanoString closes $20M Series D round of equity financing

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it has closed $20 million in a Series D round of equity financing.

From NanoString Technologies 7 Nov 2011

MicroRNAs may predict risk of recurrence in post-resection gastric cancer patients

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces that results from a joint study by researchers at the Institutes of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital and Golda-Hasharon Hospital in Petach-Tikva, Israel show that in post-resection gastric cancer patients microRNAs may serve to predict the risk of recurrence.

4 Nov 2011

Asuragen introduces ARQ IS Calibrator Panels to improve BCR-ABL1 testing for CML

Asuragen, Inc. announced today that it has commercially launched the ARQ IS Calibrator Panels (RUO), intended to aid laboratories with standardization of BCR-ABL1 quantitative measurements on the International Scale.

31 Oct 2011

DNA synbodies, a new class of affinity reagents, gets major NIH boost

An ongoing Arizona State University effort to develop a revolutionary class of reagents that holds great promise for the future of medicine has received a major boost with a three-year, $4 million award from the National Institutes of Health.

24 Oct 2011

NanoString introduces nCounter Analysis System

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the launch of its second generation nCounter Analysis System.

From NanoString Technologies 13 Oct 2011

New robust technique holds promise for identifying trace mutant DNA sequences

Molecular DNA testing methods offer clinicians powerful tools that serve to confirm or identify disease diagnoses. High sensitivity and high specificity, however, are frequently a challenge to achieve with these methods. In a study scheduled for publication in the November issue of The Journal of Molecular Diagnostics, researchers describe a new, robust technique that holds promise for identifying trace mutant DNA sequences in an overwhelming population of unmutated DNA.

12 Oct 2011

Virtual 18F-FDG PET/CT bronchoscopy may accurately detect NSCLC metastases

For patients with non-small cell lung cancer (NSCLC) the accurate determination of the lymph node status before therapy is critical to develop an individualized treatment plan. Research from the October issue of the Journal of Nuclear Medicine highlights a new way for this information to be collected -- a virtual fly-through three-dimensional 18F-FDG PET/computed tomography (FDG-PET/CT) bronchoscopy that has high diagnostic accuracy for the detection of regional lymph node metastases.

4 Oct 2011

Quidel, Life Technologies to distribute and commercialize molecular diagnostics in Europe

Life Technologies Corporation today announced that the company has signed an agreement with Quidel Corporation to distribute and commercialize molecular diagnostic assays for the European market.

22 Sep 2011

OPTOS to acquire ophthalmic instrumentation business from OPKO

OPKO Health, Inc. has agreed to sell its ophthalmic instrumentation business to OPTOS, Inc., a subsidiary of Optos plc, a leading and rapidly growing medical technology company engaged in the design, development, manufacture and marketing of devices to image the retina of the eye. Optos will pay OPKO $17.5 million in cash at closing, plus future royalties.

22 Sep 2011

NanoString's miRGE Assay now available for use in nCounter Analysis System

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of the nCounter miRGE Assay for use on its nCounter Analysis System.

From NanoString Technologies 22 Sep 2011

OvaGene's new molecular diagnostics laboratory receives CLIA-certification

OvaGene Oncology Inc., a molecular diagnostics company specializing in the development and commercialization of personalized gene-based diagnostics for gynecologic cancer, announced today that the company has received Clinical Laboratory Improvement Act (CLIA) certification for their newly constructed state-of-the-art molecular diagnostics laboratory.

20 Sep 2011

Hologic to showcase automated systems for cervical cancer screening at IPV, Berlin

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will focus on two new, ready-to-market automated options for cervical cancer screening at the International Papillomavirus Conference & Clinical Workshop (IPV) September 17th through 22nd in Berlin, Germany.

From Hologic, Inc. 17 Sep 2011

AmerisourceBergen completes acquisition of Premier Source

AmerisourceBergen Corporation today announced that it has completed the acquisition of Premier Source, a privately held company that provides consulting and reimbursement services to medical device, pharmaceutical, molecular diagnostic, and biotechnology manufacturers, as well as other health services companies.

2 Sep 2011

HTG announces availability of qDiscovery miRNA WTA Version 16

HTG Molecular Diagnostics today announced the availability of the qDiscovery miRNA Whole Transcriptome Array (WTA) Version 16, a complete solution for microRNA (miRNA) analysis on any sample type or size.

30 Aug 2011

QIAGEN acquires Cellestis

QIAGEN N.V. today announced that its acquisition of all the ordinary shares in Cellestis Limited by a way of a scheme of arrangement has been implemented.

From QIAGEN Manchester Limited 29 Aug 2011